NCT00323375View on ClinicalTrials.gov

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

PHASE1CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

August 1, 1999

Primary Completion Date

June 30, 2005

Study Completion Date

August 31, 2005

Conditions

Malaria

Interventions

DRUG

AQ-13

A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).

DRUG

Chloroquine (CQ) Treatment

A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).

Trial Locations (1)

70112

Tulane-LSU-Charity Hospital General Clinical Research Center, New Orleans

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Tulane University Health Sciences Center

OTHER

NCT00323375 - Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine | Biotech Hunter | Biotech Hunter